Replies to post #628 on Spectrum Pharmaceutecals Inc (SPPI)

[fxchat]

Indeed, SPPI is going to do their crazy run to $9 again due to pending approval of FUSILEV

FUSILEV is already approved in EUROPE, and was approved for another disease by FDA last year.

SO this means 99.9999999% approval!

With approval of Fusilev, they can increase their revenue from FUsilev by 2X!

Now Fusilev is selling $9mln per quarter. That's $36mln per quarter.

With this approval, there will be more target patients, and expect more than double revenue which is $72mln!

SPPI market cap is only $300mln now. Really low.

Zevalin sales may top $180mln, so we may see a target revenue of $250mln by 2010.

That will put SPPI in the league of the $250mln revenue medical stock. Which usually have market cap of 1bln or more.

So expect SPPI to have that market CAP and we will see 3X gains.

SPPI will be $20 by year end.

They still got eoquin. bladder cancer drug which is crazily expensive too!

BUY in today should not be wrong. The most u can trade this n sell at $9.